• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

LAMIVUDINE Drug Record

  • Summary
  • Interactions
  • Claims
  • LAMIVUDINE chembl:CHEMBL141 Approved

    Alternate Names:

    LAMIVUDINE
    ZEFFIX
    BCH 189, (-)-
    EPIVIR
    EPIVIR-HBV
    GR-109714X
    HEPTOVIR
    BETA-L-3'-THIA-2',3'-DIDEOXYCYTIDINE
    (-)-2'-DEOXY-3'-THIACYTIDINE
    (-)-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)CYTOSINE
    LAMIVUDINA
    LAMIVUDIN
    LAMIVUDINUM
    BETA-L-2',3'-DIDEOXY-3'-THIACYTIDINE
    2',3'-DIDEOXY-3'-THIACYTIDINE
    3TC
    3'-THIA-2',3'-DIDEOXYCYTIDINE
    drugbank:00709
    rxcui:68244
    pubchem.compound:60825
    chemidplus:134678-17-4
    chembl:CHEMBL141

    Drug Info:

    (2 More Sources)

    Publications:

    Flisiak et al., 2004, Effect of lamivudine treatment on plasma levels of transforming growth factor beta1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B., World J. Gastroenterol.
    Olson et al., 2002, The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1)., AIDS
    Weiss J et al., 2007, Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors., Drug Metab Dispos
    Coelho AV et al., 2013, ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients., J Clin Pharmacol
    Sankatsing et al., 2007, Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy., J. Infect. Dis.
    Gur et al., 2005, Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?, BMC Gastroenterol
    Halvas et al., 2000, Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine., J. Virol.
    Habtewold A et al., 2013, Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients., Pharmacogenomics J
    Selimoglu et al., 2005, Is leptin a predictive factor in the end of therapy response in chronic hepatitis B?, Pediatr Int
    Torres et al., Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations., Environ. Mol. Mutagen.
  • LAMIVUDINE   CHPT1

    Interaction Score: 2.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   PCYT2

    Interaction Score: 2.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   HPRT1

    Interaction Score: 2.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17358033


    Sources:
    NCI

  • LAMIVUDINE   PGK1

    Interaction Score: 2.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   PCYT1A

    Interaction Score: 2.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   NT5C

    Interaction Score: 1.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   ENOSF1

    Interaction Score: 0.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10864683


    Sources:
    NCI

  • LAMIVUDINE   SLC22A3

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   CMPK1

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   NME2

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   APOA1

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17538878


    Sources:
    NCI

  • LAMIVUDINE   NME1

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   SLC22A2

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   LEP

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16091072


    Sources:
    NCI

  • LAMIVUDINE   ABCC3

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17172311


    Sources:
    DTC PharmGKB

  • LAMIVUDINE   ABCC1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12218384 17172311 23996099


    Sources:
    DTC NCI PharmGKB

  • LAMIVUDINE   PTH

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16171525


    Sources:
    NCI

  • LAMIVUDINE   MMP1

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15309715


    Sources:
    NCI

  • LAMIVUDINE   DCK

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   SLC22A1

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   ABCC2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17172311


    Sources:
    DTC PharmGKB

  • LAMIVUDINE   CYP2B6

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23089673


    Sources:
    PharmGKB

  • LAMIVUDINE   HLA-B

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   ABCC4

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   ABCG2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LAMIVUDINE   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23996099


    Sources:
    PharmGKB

  • NCI: 3TC

    • Version: 14-September-2017

    Alternate Names:
    C1471 NCI drug code

    Drug Info:

    Publications:
    Sankatsing et al., 2007, Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy., J. Infect. Dis.
    Torres et al., Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations., Environ. Mol. Mutagen.
    Halvas et al., 2000, Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine., J. Virol.

  • NCI: LAMIVUDINE

    • Version: 14-September-2017

    Alternate Names:
    C1471 NCI drug code

    Drug Info:

    Publications:
    Gur et al., 2005, Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?, BMC Gastroenterol
    Selimoglu et al., 2005, Is leptin a predictive factor in the end of therapy response in chronic hepatitis B?, Pediatr Int
    Flisiak et al., 2004, Effect of lamivudine treatment on plasma levels of transforming growth factor beta1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B., World J. Gastroenterol.

  • DTC: LAMIVUDINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL141 ChEMBL Drug ID

    Drug Info:

    Publications:
    Weiss J et al., 2007, Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors., Drug Metab Dispos

  • PharmGKB: lamivudine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Habtewold A et al., 2013, Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients., Pharmacogenomics J
    Coelho AV et al., 2013, ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients., J Clin Pharmacol

  • TTD: Lamivudine

    • Version: 2020.06.01

    Alternate Names:
    D07TQV TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL141

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21